肺癌是全球癌症相关死亡的首要原因，其中非小细胞肺癌 (NSCLC) 占病例的 85-90%。靶向治疗是 NSCLC 最基本的治疗选择，其他常见的治疗方法包括放射治疗、手术、化疗和免疫治疗。我们的研究目的是从 18 项随机对照试验中提取，估计无进展生存期 (PFS) 是否是 NSCLC 的一个结果以多西紫杉醇为实验组，抗肿瘤药、激酶抑制剂和单克隆抗体为对照组。我们使用Google Scholar、PubMed、Scopus、Science Direct和Cochrane Library选择了2011年至2022年发表的相关研究。搜索中包含晚期 NSCLC、化疗、RCT、多西他赛和二线治疗等术语。 18 项已确定的研究总共对 9738 名患者进行了评估。我们使用R Studio的meta包来进行meta分析。使用图形漏斗图直观地评估发表偏倚。接受基于多西他赛的治疗的患者的 PFS 比接受抗肿瘤药物、激酶抑制剂或基于单克隆抗体的治疗的患者要长得多。总体荟萃分析显示，标准治疗组患者的 PFS 略长于实验治疗组患者。随着 PFS 的广泛应用，多西紫杉醇在晚期 NSCLC 二线治疗中的表现优于单克隆抗体、抗肿瘤药物和激酶抑制剂.版权所有 © 2024 N、Jain、C、Shreevatsa、Rajendrasozhan、Dharmashekar、Suresh、Patil、Singh、Vishwanath、Srinivasa、Kollur 和 Shivamallu。

Lung cancer is the foremost cause of cancer-related death globally, with non-small cell lung cancer (NSCLC) accounting for 85-90% of cases. Targeted therapy is the most essential therapeutic option for NSCLC, other common treatments include radiation therapy, surgery, chemotherapy, and immunotherapy.Our study objective was to estimate whether progression-free survival (PFS) is an outcome of NSCLC extracted from 18 randomized control trials (RCTs) with docetaxel as experimental group and antineoplastic agent, kinase inhibitor, and monoclonal antibodies as a control group.We selected relevant studies published between 2011 and 2022 using Google Scholar, PubMed, Scopus, Science Direct, and Cochrane Library. Advanced NSCLC, chemotherapy, RCT, docetaxel, and second-line treatment were the terms included in the search. A total of 9738 patients were evaluated from the 18 identified studies. We used the meta package of R Studio to perform the meta-analysis. Graphical funnel plots were used to evaluate publication bias visually.Patients who underwent docetaxel-based therapy had a considerably longer PFS than those who got antineoplastic agents, kinase inhibitors, or monoclonal antibodies-based treatment. Patients in the standard treatment arm had a slightly longer PFS than those in the experimental therapy arm in the overall meta-analysis.Docetaxel outperformed monoclonal antibodies, antineoplastic agents, and kinase inhibitors in the second-line therapy of advanced NSCLC since PFS was extensively utilized.Copyright © 2024 N, Jain, C, Shreevatsa, Rajendrasozhan, Dharmashekar, Suresh, Patil, Singh, Vishwanath, Srinivasa, Kollur and Shivamallu.